The surgical management of women with ovarian cancer in the south west of England

A Olaitan¹, J Weeks², A Mocroft³, J Smith¹, K Howe¹, and J Murdoch¹

¹Department of Gynaecological Oncology, St Michael's Hospital, Southwell Street, Bristol, BS2, 8EG; ²Regional Cancer Organisation, Avon Health Authority; ³Department of Primary Care & Population Sciences, Royal Free & University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK

Summary The surgical management of epithelial ovarian cancer in the South West of England was studied in the two years 1997–1998 in order to determine the factors that influence the outcome of surgery and to provide a baseline from which to assess the effect of centralisation of cancer services. All hospitals in the South West region of England participating in the Regional Cancer Organisation's longitudinal study of outcomes in gynaecological malignancies are included. Six hundred and eighty-two patients with epithelial ovarian cancer were registered with the RCO in the two-year study period. Five hundred and ninety-five women were offered primary cytoreductive surgery of which 438 were said to be optimally cytoreduced. Applying multivariate models to analyse the outcome of surgery, older patients (OR = 0.82 per 5-year increase in age, P = 0.0003), patients treated in hospitals managing fewer than ten cases of ovarian cancer per year (OR = 1.92, P = 0.02) and patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4 (OR = 0.002, P < 0.0001) disease were less likely to be optimally cytoreduced. Gynaecological oncologists were 2.06 times more likely to attain optimal cytoreduction when compared to general gynaecologists and this was statistically significant (P = 0.01). The results from this study support the argument that limiting surgery for ovarian malignancy to specialised surgeons improves the extent of cytoreductive surgery. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: ovarian cancer; surgery; cytoreduction; gynaecological oncologist

INTRODUCTION

The publication of the Calman-Hine Report (Department of Health, 1995) on the commissioning of cancer services has focused attention on the organisation of services for gynaecological cancer. Gynaecological cancers are, by definition, rare cancers and it has been advocated that the centralisation of services will lead to improved quality of care. This assertion has been supported by several recent publications (Jackson et al, 1997), particularly relating to ovarian cancer (Junoer et al, 1994; Kehoe et al, 1994). Ovarian cancer, the commonest gynaecological cancer, has a poor outcome, with a five-year survival of 30-40% (Nguyen et al, 1993). This has been attributed, in part, to late presentation of disease, with the majority of cases having extra-ovarian spread at diagnosis (Nguyen et al, 1996). The principles employed in the treatment of epithelial ovarian cancer are consensus rather than research-based and involve surgical resection of the disease, followed by chemotherapy. Prescribed optimal cytoreductive surgery, which involves reducing the disease to less than 2 cm, can be particularly challenging in cases of advanced ovarian cancer. Previous publications have demonstrated that Gynaecological Oncological surgeons achieve better outcomes in terms of smaller residual disease after surgery (Junor et al, 1994) and improved survival (Kehoe et al, 1994; Junor et al, 1999) than their general gynaecological or surgical colleagues.

The South West region of England is a large geographical region, stretching 220 miles from Gloucester in the north of the

Received 4 September 2000 Revised 17 September 2001 Accepted 3 October 2001

Correspondence to: A Olaitan

region to Penzance at its southernmost tip. The region is served by five cancer centres: Three Counties Centre to the north of the region which serves Cheltenham. Gloucester and Hereford hospitals; Avon and Somerset cancer centre based in Bristol; Exeter and Plymouth cancer centres in the south west of the region and Dorset in the south east. Wiltshire became a part of Avon and Somerset cancer centre at the end of 1998 (See Appendix 1). The current organisation of gynaecological cancer services in the South West of England is similar to the rest of the country. The regional cancer centre receives primary referral from its catchment population and tertiary referrals of more complicated or relapsed cases from associated cancer units and district hospitals. Most ovarian cancer cases receive their primary treatment in their local hospital and are referred centrally if they require further surgery or chemotherapy. This arrangement may change in the near future following the implementation of the recently published National Health Service Executive document 'Improving Outcomes in Gynaecological Cancer' (NHS Executive, 1999). In this document, it has been advocated that all women with ovarian cancer be referred to recognised cancer centres so that they can receive optimal management for their disease, with multidisciplinary input into the planning of their management, expert surgery and chemotherapy from dedicated gynaecological surgeons and oncologists.

There are particular challenges to developing this model of care in a region with a widespread rural population. We therefore decided to study the surgical management of epithelial ovarian cancer in the South West of England in the two years 1997–1998

On behalf of: South and West Tumour Panel for Gynaecological Cancer R Anderson, P Bliss, I Boyd, T Clarke, R Counsell, J Cullimore, F Daniel, A Falconer, E Gilby, J Giles, J Graham, L Hirschowitz, A Hong, N Johnson, V Laurence, R Marshall, JB Murdoch, J Orford, JN Renninson, J Richardson, G Swingler

prior to the re-organisation of gynaecological cancer services, looking particularly at factors influencing the completeness of surgery at each stage of disease. This study, as well as providing a base-line against which future performance can be measured, enables us to estimate the increase in work load and the resource implications for the regional cancer centre if centralisation of ovarian cancer management is fully implemented.

MATERIALS AND METHODS

The South and West Regional Cancer Organisation (RCO) Gynaecology Tumour Panel is constituted of a multidisciplinary team of experts involved in the management of gynaecological malignancies. In 1997, the RCO initiated a prospective longitudinal study of the management of gynaecological cancer to establish current patterns of care and facilitate development of services in the region (Jackson et al. 1997). A one-page minimum data-set for each major gynaecological cancer site was designed (Figure 1). After obtaining approval from all units managing gynaecological malignancies, copies of the minimum data set pro forma were circulated along with guidance notes that included outlines of American Society of Anesthesiologists (ASA) grading, FIGO staging, and histopathology information required. Treatment policies detailing accepted pre-operative and operative management of epithelial ovarian cancer were produced and circulated by the RCO to all participating hospitals (Appendix 1). To ensure uniform histopathological reporting, the RCO also circulated guidelines for participating histopathologists (Appendix 2). The clinician managing the case is responsible for filling the form and for returning a copy to the RCO. The data are then entered on a central Microsoft AccessTM database managed by one of the co-authors (JW). Complete data on surgical procedures are available for 1997 and 1998.

Data for all ovarian cancer cases registered with the RCO from January 1997 to December 1998 were obtained from the RCO database. Central validation by the RCO had previously confirmed registration rates of close to 100% for all hospitals participating in 1997 (Regional Cancer Organisation, 1999). To ascertain completeness of the data and to identify outstanding cases not registered with the RCO, the histopathology departments of participating hospitals were approached for lists of patients with a histological diagnosis of ovarian cancer during the study period. Any cases thus identified were checked with the appropriate clinician, yielding some additional registrations.

The total number and FIGO stage of epithelial ovarian cancer cases managed by each contributing hospital per year was calculated. The accuracy of the FIGO stage was examined by comparing the ascribed FIGO stage with the clinico-pathological data supplied on the RCO form. These details were checked against the specialisation of the surgeon responsible for the case. Cases were re-staged by one of the authors (AO) if there was a mismatch between ascribed FIGO stage and the clinico-pathological data available. Where no FIGO stage was stated, patients were allocated a stage where there was sufficient staging information supplied on the RCO form. Sub-stages were ascribed or confirmed where this information was available. Cases were left without a clinical stage where there was insufficient clinico-pathological information available. Cases were also left unstaged where there was insufficient information to confirm the original FIGO stage allocated. The amended FIGO staging was applied in all subsequent analysis.

All cases undergoing primary surgery were classified according to extent of surgery per stage of disease. Patients with less than 2 cm residual disease at the end of surgery were classified as receiving optimal cytoreductive surgery while those with greater than 2 cm residual disease were classified as receiving suboptimal surgery.

Statistical methods

Univariate and multivariate logistic regression analyses were applied to determine the factors related to both the decision to offer surgery and on the outcome of surgery. The factors investigated included age, ASA grade, stage of disease, grade and specialisation of surgeon, consultant supervision, and the number of ovarian cancer operations per contributing hospital per year (classified as 10 or fewer cases of ovarian cancer per year or greater than 10 cases per year).

The operating surgeons were classified as general surgeons, general gynaecologists and gynaecological oncologists according to the information supplied on the RCO form. A gynaecological oncologist was defined as an RCOG-recognised sub-speciality trained individual (of which there is one in the region) or the lead Consultant for gynaecological oncology within a cancer centre. In addition, lead clinicians for gynaecological cancer within teaching or district hospitals with a large caseload (15 or more cases of ovarian cancer per surgeon per year) were included in this definition, giving a total of nine gynaecological oncologists within the region.

RESULTS

A total of 820 ovarian cancer cases were registered with the RCO in the study period 1997-1998 from 20 NHS and eight private hospitals. Of these, 36 were non-epithelial tumours. Non-epithelial cancers are not considered in this study and have been excluded from all further analyses. A further eight cases were excluded as they had secondary ovarian tumours from a non-gynaecological primary. Other exclusions included 15 patients with sychronous primaries, the second tumour being non-ovarian and 21 patients who were registered with recurrent ovarian cancer. Of the 740 remaining patients, 58 were registered by hospitals outside the south west region where we were unable to crosscheck the number of ovarian cancer cases with the histopathology department. These patients were therefore also excluded, leaving a total of 682 cases registered with the RCO with a verified diagnosis of primary epithelial ovarian cancer. This number included 129 cases of borderline epithelial tumours. The median age of these patients was 62 years (range 18-94). Figure 2 illustrates the total number of cases registered by each hospital per year. Some hospitals only started to register gynaecological cancer cases with the RCO in 1998 and this is reflected in the relatively small number of cases registered. A total of 94 surgeons, including seven general surgeons and one breast surgeon managed these cases. The median number of cases managed per surgeon over the two-year study period was four (range 1–72). Figure 3 illustrates the number of ovarian cancer cases undertaken by the lead clinician for gynaecological cancer services in each contributing hospital in the two year study period. The Dorset hospitals (see Appendix 1) are not included in this figure as they only started to register cases with the RCO in 1998.


Eighty-nine patients were re-staged because the clinicopathological information given on the RCO form did not match the FIGO stage ascribed while there were 132 cases where there was insufficient data to confirm or assign a stage, making a total of 221


| SURGERY Constitient Surgeon: Patient in Trial: yes no Trial Name ASA grade | |
|---|--|
| Main treatment: asgreg asliciturary cherothetray Hoopinal Main treatment Pattern in Trial: yes aso Trial Name | |
| SURGERY Consultant Surgeon: Paieri in Tink: yp: no: Tink Name ASA grade Which ovarian cancer operation is this: 1st 2nd 3nd 4fb heision: vertical Asster present and samplet: yp: no: Size of Largest transaut ORGANS INVOLVED ORGANS INVOLVED Recary: yp: no: Size of Largest transaut ORGANS INVOLVED Recary: yp: no: don't know Abdeminate president transaut ORGANS INVOLVED Recary: yp: no: don't know Abdeminate president transaut ORGANS INVOLVED Recary: yp: no: don't know Abdeminate president transaut ORGANS INVOLVED Recary: yp: no: don't know Rectary: yp: no: Preside and the invo Statil Boxet: yp: no: don't know Lower statact Appendix: yp: no: don't know Statil Boxet: yp: no: don't know Lower statact Appendix: yp: no: don't know statact Lower statact Appendix: yp: no: don't know statact Lower statact ROCEEURE Weide potepot | Postcode |
| Patient in Trial yss no Trial Name | reatment started / / |
| Patient in Trial yss no Trial Name | man and a second se |
| ASA grade Which ovarian cancer operation is thit: Ist 2nd 3nd 4ft Incision: vertical Ascing present and sampled: yes no Wachings takes (if no accles); yes no don't know Public periodename Ascing present and sampled: yes no Machings takes (if no accles); yes no don't know Aboring periodename Covary: yes no don't know Ascending color: yes no don't know Aboring periodename Lowary: yes no don't know Ascending color: yes no don't know Aboring periodename Lowary: yes no don't know Stau Blowel: yes no don't know Abore arface: Appendix: yes no don't know yes no don't know Liver parendiyma: Prisipasa-actin coles sampled: yes no Prisipasa-actin coles sampled: yes no PROCEDURE Wedge biopsy of ovary stab hotal hysterectory ormentactory arrestactory ROUCEDURE Wedge biopsy of ovary stab hotal hysterectory arrestactory no ROUCEDURE Wedge biopsy of ovary stab hotal hysterectory arrestactory arrestactory ROUCEDURE Wedge biopsy efformere nand infinite stab hotal hyst | |
| Aseite poerer and surplet: yes no Wakings takes (if no acciss): yes no Size of largest tensor ORGANS INVOLVED R vary: yes no don't know Ascending color: yes no don't know Price perionents: Largest yes no don't know Decending color: yes no don't know Liver parentsprace Darentsur: yes no don't know Decending color: yes no don't know Liver parentsprace Darentsur: yes no don't know Satall Bowel: yes no don't know Liver parentsprace Price positive yes no don't know Satall Bowel: yes no don't know Liver parentsprace Price positive yes no don't know Satall Bowel: yes no don't know Liver parentsprace Price positive yes no den't know Satall Bowel: yes no don't know Liver parentsprace Price positive yes no den't know Satall Bowel: yes no don't know Liver parentsprace Price yes no den't know Satall Bowel: yes no don't know Liver parentsprace Price yes no den't know Satall Bowel: yes no don't know Liver parentsprace Price yes no den't know Satall Bowel: yes no don't know Interestion Price yes no den't know Satall Bowel: yes no don't know Price yes no den't know Satall Bowel: yes no don't know Price yes no den't know Satall Bowel: yes no don't know Price yes no den't know Satall Bowel: yes no don't know Price yes no den't know Satall Bowel: yes no don't know Price yes no yes for Price don't know Price don yes no Price differentiation well Price don't know Price differentiation well Price don't know Price find walking segary yes no Price find decorrece yes | transverse 🗌 lagarosopic |
| ORGANS INVOLVED Roay: yes: ao: don't know Averaling color: yes: ao: don't know Abdenital perimeare: Loway: yes: ao: don't know Abdenital perimeare: Abdenital perimeare: Loway: yes: ao: don't know Abdenital perimeare: Loway: yes: ao: don't know Abdenital perimeare: Loway: yes: ao: don't know Schlightragmic perimeare: Loway: yes: ao: don't know Schlightragmic perimeare: Directain: yes: ao: don't know Low stract Appendix: yes: ao: don't know Low stract Periobana-contic nodes sampled: yes: no: how strates and Don't know Low strates LSO RSO biopy of ovary and bysterectory oranial beed resection MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm 1-2cm strates and no: No: PRIMARY SURGEON: Consultant yes: ao: Spectrue (Laway): aisent? yes: no: | |
| Levary: pes do don't know Trans color: yes no don't know Abdeninal perimenent: Uterna: yes no perivisably sensored Descending color: yes no don't know Subdispingmatic perios Ornerian: yes no don't know Senal Bowel: yes no don't know Liver parenchyma: Privis/para-sontic nodes paipated no yes (normal) yes (normal) Privis/para-sontic nodes sampled: yes no PROCEDURE Wedge biopsy of ovary and hysterectump orneriachump ISO RSO biopsy ofly sub-total hysterectump small bowel reaction MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm 1-2cm clim ni visible PRIMARY SURGEON: Consultant yes no Spikeg (state Year) Supernited by somalater? yes no HISTOPATHIOLOGY Consultant Network periopentive CA125 HISTOPATHIOLOGY Consultant Mellion section ni visible Privisely of somal is present absent some periopentive CA125 HISTOPATHIOLOGY Consultant Mellion moderatery ornerated infiltrated democycarcinoms moderatery Orarian copular surface Transor deposits present absent democycarcinoms moderatery Orarian copular surface Transor deposits present absent Denotum of taken taken taken and infiltrated Perioneal flaid/washings positive regulive Other perioneal biopsies/freshings taken positive regulive Perioneal flaid/washings positive no | |
| Darma yes no den't know Subdiaphragmetic perifice Omentame yes no den't know Liver surface Appendit: yes no den't know Liver surface Pelvidpans-sortic nodes sampled: yes (normal) yes (normal) yes (normal) Pelvidpans-sortic nodes sampled: yes no Appendit: yes (normal) LSO RSO biops of vary and hysterecomy urnal bowd resection MAXIMUM SIZE OF RESIDUAL DISEASE MASS: >2cm i-2cm clon no PRIMARY SURGEON: Consultant yes no Spleag (nate Year) Spleag (nate Year) splead file PRIMARY SURGEON: Consultant yes no Spleag (nate Year) splead file no CXXR againef con ano tot ken spleag (nate Year) | yes 🗌 no 🗌 don't know |
| Direction: yes no don't know Rectam: yes no don't know Liver surface: Appendit: yes no don't know Small Bowel: yes no don't know Liver parenchyme. Privicipues-sortic nodes palpatel: no yes (romath) yes (relarged) Privicipues-sortic nodes palpatel: yes (romath) yes (relarged) PROCEDURE Wedge biopsy of orary sub hysterectumy ornentectumy ornentectumy mentions SIO RSO biopsy orall sub-total hysterectum ornentectum MAXIMUM SEE OF RESIDUAL DISEASE MASS: >2cm 1-2cm store supervised by consultant? yes no CXE: acgative positive sub-total hysterectum ornentectum no MAXIMUM SEE OF RESIDUAL DISEASE MASS: >2cm 1-2cm store store supervised by consultant? yes no CXE: acgative positive sub-total hysterectum moderately no MAXIMUM SEE OF RESIDUAL DISEASE MASS: >2cm 1-2cm store store sub-total hysterectum no MAXIMUM SEE OF RESIDUAL DISEASE MASS: >2cm 1-2cm store store store no no no MAXIMUM SEE OF RESIDUAL DISEASE MASS: >2cm store store store store no no no MAXIMUM SEE OF R | yes 🗔 no 🛄 don't know |
| Appendit: yes no don't know Senall Bowel: yes no don't know Liver pareachyma: Perkicipana-sortic nodes pulpated no yes inormalit yes intellarged) Perkicipana-sortic nodes sampled: yes no mail hysterectury ormestectury mail hysterectury ormestectury mail hysterectury host hos | neum: yes 🗌 no 🗌 don't know |
| Privicipana-aorie nodes palpateit noyes (normal)yes (enlarged) Privicipana-aorie nodes sampled: yes no PROCEDURE Wedge biopsy of ovary and hysterectomy ormentectumy ISO RSO biopsy only and hysterectomy arrall bewel reaction MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm rism is visible RUMARY SURGEON: Consultant yes no Softeg (wate Year) Supervised by measurant? yes no RECOMMARY SURGEON: Consultant yes no Supervised Dy measurant? yes no REMARY SURGEON: Consultant yes epithelial tadenokcarcinoma HISTOPATHOLOGY Consultant Histopathelologist: HISTOPATHOLOGY Consultant Histopathelologist: HISTOPATHOLOGY Consultant Histopathelologist: Deviana capadar surface advant epithelial tadenokcarcinoma Divatian capadar surface not taken advant Deviana dispate/ not taken | yes 🗌 no 🗌 don't know |
| Period reproduction PROCEDURE Wedge biopsy of ovary anal bysterectory SO RSO biopsy only SO RSO BAXIMUM SEE OF RESEDUAL DISEASE MASS: >2cm PRIMARY SURGEON: Consultant yes no SpReg (state Year) Supervised by one Supervised by one PRIMARY SURGEON: Consultant yes no SpReg (state Year) Supervised by one supervised by one PRIMARY SURGEON: Consultant yes INSTOPATIFICIOGY Consultant Histopantbologist: HISTOPATHOLOGY Consultant Histopantbologist: Histological differentiation well Datation apsular surface Timour deposits present Datation apsular surface taken and infiltrated Contraiternol Ovary not taken Perioneal Biopsizes/brashings taken positive Perioneal Biopsizes/brashings taken positive ChemotherRAPY Treatment of recurrence Patient in Trut yes Responic CK Patient in Trut yes So Namber of previses corres ChemotherRAPY Responic Responic CK < | yes 🗌 no 🗌 don't know |
| ROCEDURE Wedge biopsy of ovary avail bysterectory omentactanty LSO RSO biopsy odly sub-total hysterectory small bowel resection MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm 1-2cm <tcn< td=""> nil visible PRIMARY SURGEON: Consultant yes no SpReg (wate Year) Siepernited by consultant? yes no PRIMARY SURGEON: Consultant yes no SpReg (wate Year) Siepernited by consultant? yes no PRIMARY SURGEON: Consultant yes not SpReg (wate Year) Siepernited by consultant? yes no PRIMARY SURGEON: Consultant yes not done Perioperative CA125 no no HISTOPATHOLOGY Consultant Histopathologeist: Histoidagical differentiation well mademicity no Outrain capular surface Tumoar deposits present abeort abeort no no Outrain capular surface Tumoar deposits present abeort abeort no no Outrain capular surface Tumoar deposits present abeort regative no Outratan n</tcn<> | |
| SO BSO biopsy oldy sub-total bysterecorres small bowel resoction MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm 1-2cm initiality RIMARY SURGEON: Consultant yes no SpReg (wate Year) Supervised by consultant? yes no RIMARY SURGEON: Consultant yes no SpReg (wate Year) Supervised by consultant? yes no RIMARY SURGEON: Consultant Histopathologist: Initiality moderately initiality HISTOPATHOLOCY Consultant Histopathologist: moderately Initiality moderately Hastology epithelial turnour of borderine malignary epithelial (adenovacinoma initiality) Initiality Outrian capadar surface Turnour deposits present absent Initiality Outrian capadar surface Turnour deposits present absent Initiality Outrian not taken taken and infiltantod taken and infiltantod Costnatarral Ovary not taken nogative nogative Datentan not taken positive nogative Other perioneal biopsies/frashings taken positive nogative | 23. 12 12 |
| MAXIMUM SIZE OF RESIDUAL DISEASE MASS: >2cm +2cm <icm nil="" visible="" ="" <br="">PRIMARY SURGEON: Consultant yes no SpReg (state Year) Supervised by exeaultant? yes no CXR: segative positive sespectous not done Perioperative CA125 HISTOPATHOLOGY Consultant Histopathologist: Histology efference number noderately Patiology efference number noderately Ovarian capadar surface Tamour deposits present absent Disentan not taken taken and infiltrated Disentan not taken taken and infiltrated Perioneal fluid/vashings positive negative Disentan not taken taken and infiltrated Perioneal fluid/vashings positive negative Disentan bowel live Other organ involvement bowel live Patient in Trial yes so Trial Name CHEMOTHERAPY First Line yes so Trial Name Perioneal debuking sorgery yes so Namber of previous courses Perioneal debuking sorgery yes so Namber of previous courses Perioneal debuking sorgery yes so Namber of previous courses Perioneal debuking sorgery yes so Namber of previous courses Patient in Trial Perioneal Patient in Trial Perioneal Perioneal debuking sorgery Patient </icm> | large bowel resoction |
| RIMARY SURGEON: Consultant yes no SpReg (wate Year) Supervised by consultant? yes no CXR: aegative positive associants not done Perioperative CA125 | appendicectomy [] |
| CXR: segative positive suspicessus not done Perioperative CA125 HISTOPATHOLOGY Consultant Histopathologist: finishingy reference number | |
| HISTOPATHOLOGY Consultant Histopathologist: finishing reference number | |
| Histology reference number | FIGO Stage |
| Hisology epithelial turnour of borderline malignancy epithelial tadenox/arctinoma Hisological differentiation well moderately Duratian capsular surface Tamoar deposits present absent Duratian capsular surface not taken taken and infitured Duratian capsular surface not taken taken and infitured Duratian capsular surface not taken taken and infitured Duratian capsular surface positive taken and infitured Contralateral Ovary not taken taken and infitured Contralateral Ovary not taken regative Perionecal fluid/washings positive regative Contralateral Ovary positive regative Contralateral Ovary positive regative Contralateral Divosice/Brushings taken positive regative Other organ involvement bowel liner Other organ involvement position Oncologists! regative Patient in Trial yes so Namber of previous courses Chemotrifierapy Regime so Namber of previous courses | ******* |
| Hisological differentiation well moderately Duratian capsular surface Turnour deposits present absent Directians not taken taken and infilmated Directians not taken taken and infilmated Contralisteral Ovary not taken taken and infilmated Perioseal fluid/washings positive negative Perioseal fluid/washings positive negative Cher peritoneal biopsies/breakings taken positive negative Other organ involvement howel liter ONCOLOGY Consultant Oncologist: negative ONCOLOGY Consultant Oncologist: Present Other organ involvement howel Trial Name Patient in Trial yes no ChemotrierRAPY no Namber of previous courses First Line yes no Following debuking surgery yes no Number of cycles CK PR RADIOTHERAPY Kesponic CK RADIOTHERAPY RADIOTHERAPY | |
| Duarian capadar surface Tamoar deposits present absent Ducentam not taken taken and infiltrated Ducentam not taken taken and infiltrated Contralateral Ovary not taken taken and infiltrated Perioneal fluid/washings positive negative Perioneal fluid/washings positive negative Contralateral Ovary not taken negative Perioneal fluid/washings positive negative Cher organ involvement bowel negative Doter organ involvement bowel negative ONCOLOGY Consultant Oncologist: negative Patient in Trialt yes no Patient in Trialt yes no ChemotinerApy requires of previous courses perious courses Following debuking sargery yes no Number of cycles Responic CR Ration fluerApy Responic CR Ration fluerApy Responic CR | othermon-epithelial [] |
| Discentian not taken taken and infiltrated Contralateral Ovary not taken taken and infiltrated Perionecal fluid/washings positive negative Perionecal fluid/washings positive negative Cher perionecal biogsize/brashings taken positive negative Other organ involvement bowel licer Other organ involvement bowel licer Other organ involvement bowel licer Other organ involvement bowel negative Patient in Triat yes no Patient in Triat yes no Patient in Triat yes no Polowing debulking surgery yes no Following debulking surgery yes no Number of previous courses courses ChemOTHERAPY no Number of cycles Kesponic Regine name | poorly differentiated |
| Contrabateral Ovary not taken taken and infiburated Perionecal fluid/washings positive regative Lymph nodes positive regative Deter perionecal biopsice/brashings taken positive negative Other organ involvement howel negative Iter organ involvement howel negative ONCOLOGY Consultant Oncologist: negative Patient in Trial: yes no CHEMOTHERAPY negative negative First Line yes no Number of recurrence Following debuiking surgery yes no Number of previous courses CHEMOTHERAPY negetive negetive negetive States and negetive negetive negetive Regime name | |
| Perioneal flaid/washings positive negative | taken and not infiltrated |
| Lymph nodes positive | taken and not infiltrated |
| Other peritoneal biopsies/brashings taken positive | |
| Other organ involvement howel liver ONCOLOGY Consultant Oncologist: Patient in Trial: yes no Patient in Trial: yes no CHEMOTHERAPY TREATMENT INTENT First Line yes no Following debuiking surgery yes no CHEMOTHERAPY KEGIME Number of previous courses | not biopsind 🗌 |
| ONCOLOGY Consultant Oncologist: Patient in Truit. yes _ no _ Trial Name CHEMOTHERAPY TREATMENT INTENT First Line yes _ no _ Treatment of recurrence yes _ no Following debulking surgery yes _ no _ Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CRR RADIOTHERAPY TREATMENT INTENT | |
| Patient in Tital: yes _ no _ Tital Name | other 🗔 |
| CHEMOTHERAPY TREATMENT INTENT First Line yes no Treatment of recurrence yes no Following debuiking surgery yes 10 0 Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT | A PROPERTY AND A PROPERTY |
| TREATMENT INTENT First Line yes no Treatment of recurrence yes no Following debulking sargery yes no Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT | |
| First Line yes no Treatment of recurrence yes no Following debuilking surgery yes no Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT | |
| Following debulking surgery yes 0 to 0 Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles CR PR RADIOTHERAPY TREATMENT INTENT | |
| CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT | 0 |
| Regime nameResponse CR PR Number of cyclesResponse CR PR RADIOTHERAPY TREATMENT INTENT | |
| Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT | |
| RADIOTHERAPY TREATMENT INTENT | |
| TREATMENT INTENT | 5D PD |
| | |
| | |
| | |
| RADIOTHERAPY REGIME | |

White copy - Return to RCO Yellow copy - Gynaecology notes like copy - Oncology notes Pink copy - Oncologist's records Green copy - Gynaecologist's records

Figure 1 Regional Cancer Organisation Registration Pro forma










Figure 3 Number of ovarian cancer cases/lead clinician in two-year study period

(32.5%) unsatisfactorily staged cases. Table 1 describes the restaging action taken classified according to the specialisation of the surgeon managing the case. Staging was accurate in 81.6% of cases managed by gynaecological oncologists, 62.8% of cases managed by general gynaecologists and 32.1% of cases managed by general surgeons.

Five hundred and ninety-five patients (87.2%) were managed surgically while 69 (9.9%) had laparoscopy and biopsy only. In 438 (81.2%) of the surgical cases, the Consultant was the primary surgeon. In 14 cases, the grade of the primary surgeon was not indicated. The remaining 98 were operated on by surgeons in non-Consultant grades, specialist registrars in the majority of cases. Sixty-two (63.0%) of these procedures were undertaken under Consultant supervision. In all 545 (92%) of procedures were performed by consultants or under consultant supervision. The surgeons undertaking ovarian cancer surgery without supervision included specialist registrars in year 3 (three cases), year 4 (three cases), year 5 (12 cases) and nine cases undertaken by a variety of non-consultant grade surgeons including staff grade doctors.

The amended FIGO stage at presentation of patients who underwent definitive surgery and those who did not is described in Table 2. Table 3 shows the ASA grade of patients undergoing surgery compared with those managed conservatively.

Four hundred and thirty-eight (73.8%) were described as having less than 2 cm of residual disease after surgery while 119 women had more than 2 cm of residual disease. Table 4 describes the FIGO stage at presentation of these patients and the cytoreductive rates tabulated against the operating surgeon's specialisation.

Applying univariate analysis to determine the factors influencing the decision to undertake surgery revealed that patients were less likely to be offered surgery if they were of older age (odds ratio (OR) per 5-year increase in age = 0.89, P = 0.005), in ASA grade 3 or 4 (OR 0.30, P < 0.0001) and had FIGO stage 4 disease at presentation (OR=0.10, P < 0.0001). In multivariate analyses, age was no longer significant, but patients in ASA grade 3 or 4 remained significantly less likely to be offered surgery (OR 0.3, P < 0.0001), as were patients in FIGO stage 4 (OR 0.10, P = 0.0001). In addition, in multivariate analyses, there was no significant difference in the likelihood of undergoing surgery by the

 Table 2
 FIGO stage of ovarian cancer at presentation comparing patients

 who underwent primary surgery with those who did not
 Image: Comparing patients

| FIGO Stage | Total no. of cases (%) | Total no. with surgery (%) | Total no. no surgery (%) | | |
|---------------|---------------------------|-------------------------------|-----------------------------|--|--|
| I | 156 (22.9) | 155 (22.7) | 1 (1.2) | | |
| 11 | 51 (07.5) | 51 (7.4) | 0 (0.0) | | |
| 111 | 318 (46.6) | 272 (39.9) | 46 (6.7) | | |
| IV | 24 (3.5) | 13 (1.9) | 11 (1.6) | | |
| Unstated | 133 (19.5) | 104 (15.2) | 29 (4.3) | | |
| Total | 682 (100) | 595 (87.2) | 87 (12.8) | | |

 Table 3
 ASA grades of patients undergoing surgery compared with those who had no surgery

| ASA grade | Total no. of cases (%) | Total no with surgery (%) | Total no with no surgery (%) | | |
|--------------|---------------------------|---------------------------|---------------------------------|--|--|
| 1 | 293 (43.0) | 277 (40.6) | 16 (2.3) | | |
| 2 | 204 (29.9) | 179 (26.2) | 25 (3.7) | | |
| 3 | 104 (15.2) | 78 (11.4) | 26 (3.8) | | |
| 4 | 8 (1.2) | 4 (0.6) | 4 (0.6) | | |
| not stated | 73 (10.7) | 57 (8.4) | 16 (2.3) | | |
| Total | 682 (100) | 595 (87.2) | 87 (12.8) | | |

 Table 1
 Amended stage of ovarian cancer classified according to specialisation of responsible surgeon

| Specialisation | No Change | Down- staged | Up- staged | Staged | Up-substage | Down-substage | No Stage | Total |
|----------------|--------------|-----------------|---------------|--------|-------------|---------------|----------|------------|
| Gynae | 243 | 27 | 10 | 19 | 4 | 5 | 79 | 387 (56.7) |
| Gynae-Onc | 199 | 5 | 5 | 5 | 0 | 1 | 29 | 244 (35.8) |
| Surgeon | 9 | 2 | 1 | 0 | 0 | 0 | 16 | 28 (4.1) |
| Not Stated | 10 | 3 | 1 | 1 | 0 | 0 | 8 | 23 (3.4) |
| Total | 461 | 37 | 17 | 25 | 4 | 6 | 132 | 682 |
| %) | (67.5) | (5.4) | (2.5) | (3.7) | (0.6) | (0.9) | (19.4) | (100) |

| FIGO stage | Gynaecologist 341 | | Gynaecological oncologist 219 | | Surgeon 20 | | | Unstated 15 | | | Total 595 | | |
|---------------|----------------------|--------|----------------------------------|--------|---------------|-------|-------|----------------|-------|-------|--------------|-------|-----|
| Total | < 2 cm | > 2 cm | Unst | < 2 cm | >2 cm | Unst. | <2 cm | >2 cm | Unst. | <2 cm | >2 cm | Unst. | |
| 1 | 94 | 1 | 7 | 46 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 152 |
| 11 | 23 | 1 | 1 | 20 | 0 | 0 | 1 | 0 | 2 | 4 | 0 | 1 | 53 |
| III | 67 | 66 | 7 | 82 | 36 | 6 | 1 | 3 | 1 | 3 | 0 | 1 | 273 |
| IV | 0 | 6 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Unst. | 62 | 1 | 5 | 20 | 0 | 1 | 10 | 1 | 0 | 2 | 0 | 3 | 105 |
| Total | 246 | 75 | 22 | 172 | 36 | 9 | 13 | 4 | 3 | 10 | 0 | 5 | 595 |
| % | 71.8 | 22.0 | 6.2 | 77.6 | 18.3 | 4.1 | 65.0 | 20.0 | 15.0 | 66.7 | 0.0 | 33.3 | 100 |

Table 4 FIGO stage of patients undergoing optimal cytoreductive surgery classified according to surgeon's specialisation

Unst = Unstated

caseload of the hospital (OR = 1.01, P = 0.97) or by the specialisation of the surgeon (OR = 1.33, P = 0.32) when comparing gynaecological oncologists with general gynaecologists.

These factors also had an effect on the outcome of surgery. In multivariate models, older patients were less likely to be optimally cytoreduced (OR = 0.82 per 5-year increase in age, P = 0.0003). Similarly patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4 (OR = 0.002, P < 0.0001) disease were less likely to be optimally cytoreduced. Patients treated in hospitals managing fewer than 10 cases per year were less likely to be optimally cytoreduced (OR = 1.92, P = 0.02) compared to those treated in hospitals managing 10 or more cases per year. ASA grade appeared to have no effect on the extent of surgery. Gynaecological oncologists were significantly more likely to attain optimal cytoreduction when compared to general gynaecologists (OR = 2.06, P = 0.01) while general surgeons were less likely to attain optimal cytoreduction although this difference was not statistically significant (OR = 0.30, P = 0.18).

DISCUSSION

The peculiar geography of the South West Region may make centralisation of gynaecological cancer services particularly challenging. The large expanse of rural and sparsely populated land means that there are several hospitals serving relatively small populations. Consequently, the majority of surgeons participating in this survey managed fewer than ten cases of ovarian cancer per year. The median number of cases per surgeon was four and over half of the lead surgeons for cancer services were operating on fewer than ten cases of ovarian cancer per year. The need to maintain a critical volume of work in order to sustain surgical expertise has been extensively discussed (Department of Health 1995; Jackson et al, 1997). Trimbos et al (2000), using surgery for cervical cancer as a model, demonstrated that there is a long learning curve associated with surgery for gynaecological cancer. They demonstrated a reduction in operative blood loss and operating time achieved by the same operating team over a period of thirteen years.

Eighty-nine patients (13%) required re-staging due to discrepancies between the ascribed FIGO stage and the clinico-pathological data supplied on the RCO form. One hundred and thirty-two patients (19.4%) could not be allocated a stage because there was insufficient staging data available on the RCO form. The majority of cases managed by gynaecological oncologists were accurately staged but this proportion was decreased in general gynaecologists and more so for general surgeons where, in the majority of cases, there was insufficient staging information recorded. Accurate staging is of critical importance as the decision about whether to recommend adjuvant therapy is based on this. In addition, analyses of survival data become meaningless if the correct FIGO stage is not established at the outset.

Although the same selection criteria for surgery were apparently applied through all centres, with older, less fit women being less likely to be offered surgery, hospitals that managed more than ten cases of ovarian cancer a year achieved better optimal cytoreduction rates than those managing ten or fewer cases per. In keeping with previous published reports (Junor et al, 1994; Kehoe et al, 1994), sub-specialist gynaecological oncologists achieved significantly better optimal cytoreduction rates than their non-sub-specialist colleagues although the majority of operations were carried out by general gynaecologists. The improved cytoreduction rates achieved by gynaecological oncologists (as defined by this paper) may reflect their higher case volume. There is only one RCOG-recognised subspecialty trained gynaecological oncologist in the region and so the other 'gynaecological oncologists' included in this analysis were defined by their work-load. The more widespread introduction of sub-specialty training in gynaecological oncology will, in future, allow tighter definitions of specialists and consequently, more specific analyses.

Although there are no randomised controlled trials analysing the effect of optimal cytoreductive surgery on median survival, a large number of retrospective studies have documented a favourable prognostic effect on median survival (Hogberg et al, 1993; Marsoni et al, 1990). A meta-analysis of 58 studies showed that maximum cytoreductive surgery produced a small improvement in median survival time (Hunter et al, 1992).

It is of concern that, although this happened infrequently, a number of junior doctors undertook surgery for ovarian cancer without supervision. However, the RCO does not routinely collect data about which cases were undertaken as emergencies and it may be that some of these cases presented acutely and that there was no prior suspicion of cancer. Appropriately, the majority of operations (92%) were undertaken by or supervised by Consultants.

The main drawback of this analysis is the failure to include data on chemotherapy. There is a lag phase of up to six months between surgery and completion of chemotherapy and the data for 1998 are as yet, incomplete. We would aim to include chemotherapy data in our subsequent analysis.

The follow-up period in this study is too short to examine survival, particularly as chemotherapy data are incomplete. However, previous publications (Junor et al, 1999) have shown a survival advantage in patients operated on by gynaecological oncologists over general gynaecologists or surgeons. Longitudinal follow-up is on-going and we should be in a position to analyse survival next year with the advantage of prospectively collected data.

ACKNOWLEDGEMENTS

This analysis would not have been possible without the co-operation of the Consultants from all participating hospitals who worked hard to ensure that the RCO forms were completed and promptly returned.

REFERENCES

- Department of Health, May 1995. A policy framework for commissioning cancer services. Guidance for purchasers and providers of cancer services.
- Hogberg T, Carstensen J and Simonsen E (1993) Treatment results and prognostic factors in a population-based study of ovarian cancer. Gynecol Oncol 48: 38–49
- Hunter RW, Alexander ND and Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166: 504-511

- Jackson S, Murdoch J, Howe K et al (1997) The management of cervical carcinoma within the South West region of England. Br J Obstet Gynaecol 104: 140-144
- Junor EJ, Hole DJ and Gillis CR (1994) Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 70: 363-370
- Junor EJ, Hole DJ, McNulty et al (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish study of 1866 patients. Br J Obstet Gynaecol 106: 1130-1136
- Kehoe S, Powell J, Wilson S et al (1994) The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 70: 1014-1017
- Marsoni S, Torri V, Valsecchi MG et al (1990) Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 62: 444-450
- Nguyen NH, Averette HE, Hoskins W et al (1993) National survey of ovarian carcinoma IV. Critical assessment of current International Federation of Obstetrics and Gynaecology Staging System. Cancer 72: 3007-3011
- NHS Executive, July 1999. Improving Outcomes in Gynaecological Cancers: Guidance on Commissioning Cancer Services.
- Regional Cancer Organisation, April 1999. Management of Gynaecological Carcinoma in the South West of England. South & West.
- Trimbos JB, Hellebrekers BWJ, Kenter GG, Peters LAW and Zwinderman KH (2000) The long learning curve of gynaecological cancer surgery: an argument for centralisation. BJOG 107: 19-22

APPENDIX 1 Contributing hospitals

| | С | ancer Centre 1997 | Hospital | | | | |
|---------|----|-------------------|---------------------------|--|--|--|--|
| NHS | 1 | Plymouth | Derriford Plymouth | | | | |
| | 2 | Plymouth | Treliske RCH Truro | | | | |
| | 3 | Exeter | Exeter RD & E | | | | |
| | 4 | Exeter | NDDH Barnstable | | | | |
| | 5 | Exeter | Torbay | | | | |
| | 6 | 3 Counties | CGH Cheltenham | | | | |
| | 7 | 3 Counties | GRH Gloucester | | | | |
| | 8 | 3 Counties | Hereford County Hospital | | | | |
| | 9 | Avon & Somerset | Bath RUH | | | | |
| | 10 | Avon & Somerset | Frenchay Bristol | | | | |
| | 11 | Avon & Somerset | MPH Taunton | | | | |
| | 12 | Avon & Somerset | Southmead Bristol | | | | |
| | 13 | Avon & Somerset | St Michael's Bristol | | | | |
| | 14 | Avon & Somerset | Weston General | | | | |
| | 15 | Avon & Somerset | Yeovil District Hospital | | | | |
| | 16 | Wiltshire | Salisbury (Odstock) | | | | |
| | 17 | Wiltshire | Swindon Princess Margaret | | | | |
| | 18 | Dorset | Poole Hospital | | | | |
| | 19 | Dorset | Royal Bournemouth General | | | | |
| | 20 | Dorset | West Dorset Dorchester | | | | |
| PRIVATE | | | | | | | |
| | 1 | Plymouth | Duchy Cornwall | | | | |
| | 2 | Exeter | Mount Stuart | | | | |
| | 3 | 3 Counties | Cotswold Nuffield Royal | | | | |
| | 4 | 3 Counties | Winfield | | | | |
| | 5 | Avon & Somerset | Bath Clinic | | | | |
| | 6 | Avon & Somerset | Chesterfield | | | | |
| | 7 | Avon & Somerset | Glen Bristol | | | | |
| | 8 | Avon & Somerset | Somerset Nuffield | | | | |

SOUTH AND WEST REGIONAL CANCER ORGANISATION

King Square House, King Square, Bristol BS2 8EE

HISTOPATHOLOGY GUIDELINES

1. Cervical carcinoma

- *a)* Squamous carcinoma—this category includes typical squamous carcinomas showing all grades of differentiation and of both large and small cell subtypes. The category also includes papillary squamous carcinomas and condylomatous carcinomas. Micro-invasive carcinomas of squamous type should also be recorded in this category. Verrucous carcinomas (which are invariably well-differentiated) are also of squamous type and should be included in this category. However, since the behaviour of these tumours differs from the other types of squamous carcinoma, in addition to ticking the "squamous" box on the form, please write "verrucous" alongside the box as well.
- b) Adenocarcinoma—adenocarcinomas of endocervical, endometrial papillary serous, clear cell and enteric types are all included in this category as is minimal deviation adenocarcinoma. Early invasive adenocarcinoma should also be recorded.
- c) Other—adenosquamous carcinomas, mixed tumours, small cell carcinomas (basaloid, neuroendocrine), undifferentiated carcinoma, glassy cell carcinoma, adenoid cystic carcinoma and malignant mixed mesodermal (Mullerian) tumours.

2. Endometrial carcinoma

- *a)* Usual type—endometrioid adenocarcinomas are deemed to be of "usual type". This category includes endometrioid adenocarcinomas with squamous/morular metaplasia, secretory carcinomas, papillary and ciliated cell variants.
- b) High grade type—this category includes papillary serous adenocarcinomas, clear cell, adenosquamous, squamous and undifferentiated carcinomas.
- c) Other-malignant mixed mesodermal/Mullerian tumours and any other tumours not included in categories a) or b) above.

3. Ovarian carcinoma

- *a)* Borderline and invasive epithelial tumours—include serous, mucinous (endocervical and enteric), transitional/Brenner, endometrioid and clear cell/mesonephroid tumours. Undifferentiated carcinomas are also included in the invasive epithelial group.
- b) Other-this category includes all other ovarian tumours (including carcinomas arising in teratomas).

4. Vulval carcinoma

- *a)* Squamous carcinomas—include warty/condylomatous carcinoma, spindle cell squamous carcinomas, scams carcinoma with tumor giant cells and acantholytic squamous cell carcinoma.
- b) Verrucous carcinoma-is listed separately because it differs in clinical behaviour from typical squamous carcinoma.
- *c) Other*—basal cell carcinoma, mixed tumours, Paget's disease, Melanomas, adenocarcinomas arising locally within adnexal or vestibular glands and any type of carcinoma no listed in a) or b) above.